Short Interest in Celularity Inc. (NASDAQ:CELU) Increases By 50.0%

Posted by Donna Armstrong on Apr 1st, 2025

Celularity Inc. (NASDAQ:CELU – Get Free Report) was the target of a large growth in short interest in the month of March. As of March 15th, there was short interest totalling 1,560,000 shares, a growth of 50.0% from the February 28th total of 1,040,000 shares. Approximately 11.9% of the company’s stock are sold short. Based on an average daily volume of 159,900 shares, the days-to-cover ratio is presently 9.8 days.

Celularity Price Performance

NASDAQ CELU opened at $1.73 on Tuesday. Celularity has a 52-week low of $1.00 and a 52-week high of $5.69. The business has a 50 day simple moving average of $1.83 and a 200 day simple moving average of $2.21.

Institutional Investors Weigh In On Celularity

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Keynote Financial Services LLC raised its stake in shares of Celularity by 90.1% in the 4th quarter. Keynote Financial Services LLC now owns 25,023 shares of the company’s stock valued at $52,000 after purchasing an additional 11,863 shares during the period. Biltmore Family Office LLC bought a new position in shares of Celularity during the fourth quarter worth about $73,000. Two Sigma Investments LP acquired a new stake in Celularity in the 4th quarter valued at approximately $93,000. Finally, C V Starr & Co. Inc. bought a new stake in Celularity in the 4th quarter valued at approximately $1,589,000. 19.02% of the stock is currently owned by institutional investors and hedge funds.

Celularity Company Profile

(Get Free Report)

Celularity Inc, a clinical-stage biotechnology company, develops off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer, immune, and infectious diseases. It operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. The company's lead therapeutic programs include CYCART-19, an allogeneic CAR-T cell for the treatment of non-Hodkin's lymphoma (NHL) and mantle cell lymphoma (MCL); CYNK-001, an allogeneic unmodified natural killer cell that is in Phase I/II clinical trial for the treatment of acute myeloid leukemia (AML); and APPL-001, a genetically modified placental-derived mesenchymal-like adherent stromal cell for the treatment of Crohn's disease.